86 related articles for article (PubMed ID: 21518416)
1. Bladder tumours: time for a paradigm shift?
Malmström PU
BJU Int; 2011 May; 107(10):1543-5. PubMed ID: 21518416
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
4. Outcome of very large superficial bladder tumours: a 10-year experience.
Gupta SK; Parr NJ
Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
[TBL] [Abstract][Full Text] [Related]
5. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
6. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
8. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
[TBL] [Abstract][Full Text] [Related]
9. Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls.
Gaisa NT; Henkel C; Knüchel R
Curr Opin Urol; 2010 Sep; 20(5):398-403. PubMed ID: 20625299
[TBL] [Abstract][Full Text] [Related]
10. [EORTC risk tables--a new diagnostic tool in urology].
Bobiński J; Lipiński M
Pol Merkur Lekarski; 2009 Dec; 27(162):524-8. PubMed ID: 20120722
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.
Pan CC; Chang YH; Chen KK; Yu HJ; Sun CH; Ho DM
Am J Clin Pathol; 2010 May; 133(5):788-95. PubMed ID: 20395527
[TBL] [Abstract][Full Text] [Related]
12. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
[TBL] [Abstract][Full Text] [Related]
13. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
14. T-antigens in primary non-invasive and superficially invasive human urinary bladder tumors: the correlation to tumor recurrence and tumor progression. A mini-review.
Langkilde NC
Scand J Urol Nephrol Suppl; 1995; 172():45-9. PubMed ID: 8578256
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles MA
Carcinogenesis; 2006 Mar; 27(3):361-73. PubMed ID: 16352616
[TBL] [Abstract][Full Text] [Related]
16. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
17. Survival after cystectomy for invasive bladder cancer.
de Vries RR; Nieuwenhuijzen JA; Vincent A; van Tinteren H; Horenblas S
Eur J Surg Oncol; 2010 Mar; 36(3):292-7. PubMed ID: 20097512
[TBL] [Abstract][Full Text] [Related]
18. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer.
Li M; Song T; Yin ZF; Na YQ
Chin Med J (Engl); 2007 Mar; 120(6):469-73. PubMed ID: 17439739
[TBL] [Abstract][Full Text] [Related]
19. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
[TBL] [Abstract][Full Text] [Related]
20. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
